Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 - Test2 - elhamkhani - TriplyDB

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q33883887

about

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1 Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Rational antibody-based HIV-1 vaccine design: current approaches and future directions Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1 Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection.Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.

P2860

Q27489000-44A4BAD4-947C-4742-BCC3-50EA4A8B972D Q28475912-2DCD4733-4028-491E-BAD7-B833147F08B9 Q28743092-C5DCD0A7-1A0B-4088-98AC-A1ACC97D09DE Q30353580-EAE9A9DF-BDC3-4986-BC93-F7679526E6E0 Q30360326-B28AB3B5-CE61-4A35-97B4-6FD7F27A5351 Q30379200-D23E249E-7C87-4533-A15F-8C5C1643CFDC Q30490942-7E551F0F-907D-4BC3-A61A-C7E2A40324F4 Q33374701-040A7B60-63CB-40B7-A1B0-1F6FB7C18F2E Q33413784-EAF2109D-6E15-463A-8EF5-B7999329F45A Q33571825-5341E46B-8342-429A-B145-5EC95F6C0498 Q33648910-D987FE58-27FB-455A-B434-9084E4AA2D84 Q33653774-665FA83D-8923-40BD-9DF0-01A224D42878 Q33719511-D2559734-01A6-48D0-9CCA-9B40037979F5 Q33937285-7CB3E774-B2D3-4B58-886F-51F27D517FDF Q34074750-DA397D97-93B3-4A01-A7DA-AE083EDEC534 Q34204047-A2089C9C-7166-4E9A-A68D-B02FA68D2C45 Q34285680-9B36AF43-07DC-42D5-9679-5863F29ED7CD Q34299053-99A5B44D-1B9A-48B4-BF19-97613D642C8D Q34499013-52E59E92-557C-49D5-BE9D-297F84422374 Q34539819-C7E0DE70-7E2C-4C12-B313-AE49999899B5 Q34807480-211A27B6-4F39-4C39-A3AE-4B4AA5E96AEF Q35024202-473D7104-47F2-4D73-A4D4-EC06400F76F3 Q35058860-FF2E81F4-9BF4-4E1F-8984-50D215E506CC Q35077716-49B9C88E-5663-4AED-A938-442886D66244 Q35105223-D4831519-E58D-4AAB-B0E7-DD5F863ACCF5 Q35122067-605CB355-14F8-4AAC-8C21-88A2C9F8BEF1 Q35198510-7FBA0851-1A40-4AD4-ABB3-1A4BC611DF3E Q35666057-4F9B12E3-512E-46A2-B11B-037043A0187F Q35785338-4BA7FA17-2AD6-48BF-B268-59CCEAF42357 Q35826171-B636B750-3D17-4552-ADAC-27AABAA40B4E Q35826692-54937E9B-07E1-4C51-8A76-B4322472C372 Q35857221-F227796F-DCB2-4726-B847-9D74AECF09C3 Q36103090-59E5465E-A7BE-41D2-83BB-756C50A3247A Q36149102-CEE55822-6560-467F-A6C9-31639314812A Q36294739-D8B33FB6-AD30-4C7E-AEB8-1D4259CAFD82 Q36296739-F3155F82-D806-4C61-BDB4-D61DB69FC192 Q36528901-7B8AA554-31EB-49B6-BD82-17F74CBC021A Q36600380-3E162AA7-0C23-49C5-9C74-ED978F9AE3AE Q36673173-A2BCF7C9-DD65-45B2-9884-6D755D7A1EDA Q36742228-9CD6DD6E-A14E-4C27-92E4-BF3B42EDEB6C

P2860

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q33883887

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Evaluating the immunogenicity ...... immunodeficiency virus type 1

@ast

Evaluating the immunogenicity ...... immunodeficiency virus type 1

@en

type

label

Evaluating the immunogenicity ...... immunodeficiency virus type 1

@ast

Evaluating the immunogenicity ...... immunodeficiency virus type 1

@en

prefLabel

Evaluating the immunogenicity ...... immunodeficiency virus type 1

@ast

Evaluating the immunogenicity ...... immunodeficiency virus type 1

@en

P1433

Q33883887-2F7CE712-25E4-48AF-A251-91A4F4FC419E

P1476

Q33883887-AD88AB0F-A802-4C0B-B0CD-47D1DAB8C38E

P2093

Q33883887-1701285A-E699-4055-9420-B8E3F126FE14

Q33883887-3C42AF70-F887-4635-9477-04FBB6A4520B

Q33883887-5CDE6E8E-BFBC-4A50-8349-E5F84310E338

Q33883887-65745B22-7FC6-4C89-B6B6-E1795D7B00AA

Q33883887-73D6C5BC-E121-4769-A0C2-85AFB713882D

Q33883887-A6B65DFE-A414-482A-A47A-A1E1379B3082

Q33883887-ADCAEA64-0767-4E77-B755-9A5241F68042

Q33883887-D6D72877-C30A-4F28-9DE7-EB650CDF8073

Q33883887-E47AF470-90A2-411D-9A0D-3EA4F1A63EEF

Q33883887-EAA1097B-9CA1-48EB-9B04-57AA43DE55B9

P2860

Q33883887-026BBEA5-0ACE-4A9E-82D5-E63A9E1DFF06

Q33883887-032E7942-6269-401A-800D-88EADD0A347D

Q33883887-047A70A8-9799-486D-8196-73DB74F3F412

Q33883887-0C3CF27F-C29A-4D9B-A37C-0535CD017D4A

Q33883887-0CA0F04B-AFA0-432F-ABED-C5148079E804

Q33883887-0CA6D278-62B6-4843-89EC-2FBA9E6F7C0E

Q33883887-0D3FDA9C-4506-41E5-8617-082F281E181C

Q33883887-0F774EA9-5209-4956-8B0C-0077E2EB3914

Q33883887-0F82673B-7645-4500-99D0-B4D2FFEEB6A2

Q33883887-14633FBE-4106-466A-BFCD-019919B1C2E4

P304

Q33883887-4EFA21C8-AA3A-4BF1-8780-49179FC240C9

P31

Q33883887-8B51B4F1-3122-49FC-9448-E58262CA01FC

P356

Q33883887-341752DD-1535-41FD-B379-FCE9EB20692D

P433

Q33883887-EBB1D66F-6818-43C1-A15E-1264F2F13CBF

P478

Q33883887-A669BDBC-2ABA-42F0-954D-1F53A58D692B

P577

Q33883887-C592AE90-E79E-423A-8D95-CADF412B5AC2

P5875

Q33883887-063671A0-BCEC-4DBA-AB94-4F76D25D3929

P698

Q33883887-0307E19A-7DD6-4E18-B3CD-08F07E7A4398

P932

Q33883887-A35BB110-4782-4513-BAE7-434ECAE101CD

P356

JVI.79.14.8812-8827.2005

P1433

Journal of Virology

P1476

Evaluating the immunogenicity ...... immunodeficiency virus type 1

@en

P2093

Elizabeth Michael

http://www.w3.org/2001/XMLSchema#string

John P Moore

http://www.w3.org/2001/XMLSchema#string

Kelly Barnes

http://www.w3.org/2001/XMLSchema#string

Marc Kirschner

http://www.w3.org/2001/XMLSchema#string

Michael Franti

http://www.w3.org/2001/XMLSchema#string

Norbert Schülke

http://www.w3.org/2001/XMLSchema#string

Paul J Maddon

http://www.w3.org/2001/XMLSchema#string

Rogier W Sanders

http://www.w3.org/2001/XMLSchema#string

Simon Beddows

http://www.w3.org/2001/XMLSchema#string

Thomas Ketas

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter]

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

The HIV Env-mediated fusion reaction

The antigenic structure of the HIV gp120 envelope glycoprotein

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

P304

8812-8827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.79.14.8812-8827.2005

http://www.w3.org/2001/XMLSchema#string

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7748991

http://www.w3.org/2001/XMLSchema#string

P698

15994775

http://www.w3.org/2001/XMLSchema#string

P932

1168742

http://www.w3.org/2001/XMLSchema#string